IdeS

( DrugBank: IdeS / KEGG DRUG: Imlifidase )

2 diseases

ID	Disease name (Link within this page)	Number of trials
64	Thrombotic thrombocytopenic purpura	2

ID	Disease name (Link within this page)	Number of trials
221	Anti-glomerular basement membrane disease	1

64. Thrombotic thrombocytopenic purpura

Clinical trials : 92 / Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02854059 (ClinicalTrials.gov)	September 2016	27/7/2016	IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients	A Phase II Pilot Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmaco ...	Purpura, Thrombotic Thrombocytopenic	Biological: IdeS (0.25 mg/kg);Biological: IdeS (0.50 mg/kg)	Hansa Biopharma AB	University College London Hospitals	Terminated	18 Years	N/A	All	2	Phase 2	United Kingdom
2	EUCTR2016-000249-30-GB (EUCTR)	14/07/2016	19/05/2016	IDES IN ASYMPTOMATIC TTP PATIENTS	A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACO ...	Asymptomatic antibody-mediated thrombotic thrombocytopenic purpura (TTP) with low ADAMTS13 activity ...	Product Name: HMED-IdeS Product Code: HMED-IdeS Other descriptive name: IdeS	Hansa Medical AB	NULL	Not Recruiting			Female: yes Male: yes	6	Phase 2	United Kingdom

Clinical trial : 1 / Drugs : 3 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03157037 (ClinicalTrials.gov)	March 1, 2017	11/5/2017	An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeSin Anti-GBM Disease (GOOD-ID ...	An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosi ...	Anti-Glomerular Basement Membrane Disease	Biological: HMed-IdeS	Mårten Segelmark	Hansa Biopharma AB	Completed	18 Years	N/A	All	15	Phase 2	Austria;Czechia;Denmark;France;Sweden